STOCK TITAN

Cardlytics (CDLX) Stock News

CDLX Nasdaq

Welcome to our dedicated page for Cardlytics news (Ticker: CDLX), a resource for investors and traders seeking the latest updates and insights on Cardlytics stock.

Cardlytics reports as a Nasdaq-listed commerce media platform that connects advertisers with consumers through publishers’ digital channels and a card-linked offer network. Company updates commonly cover revenue, billings, consumer incentives, partner-share costs, adjusted contribution, Adjusted EBITDA, and guidance tied to advertiser demand and publisher relationships.

Recurring announcements also address governance and equity compensation under its inducement plan, capital-structure matters, and strategic portfolio actions. Recent company history includes the completed divestiture of Bridg, the identity resolution and shopper intelligence platform that had used point-of-sale data for analytics, loyalty marketing, and measurement.

Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) reported second quarter 2026 revenue of $36.9 million, down 36% year-over-year, and Billings of $65.5 million, down 34%. Adjusted Contribution was $21.3 million (–32% YoY), and Net Loss widened to $(14.9) million. Adjusted EBITDA was $1.7 million, compared with $3.0 million a year earlier.

Net loss per share from continuing operations was $(1.50) versus $(1.15), while Adjusted Net Loss per share was $(0.81) versus $(0.60). Operating cash flow was $(8.6) million and Free Cash Flow was $(10.7) million. MQUs declined 17% to 185.4 million, and ACPU fell to $0.11 from $0.14.

For the third quarter 2026, Cardlytics expects Billings of $61–$67 million, Revenue of $34–$39 million, Adjusted Contribution of $20–$23 million, and Adjusted EBITDA between $0 and $3 million, all implying year-over-year declines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.94%
Tags
-
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) reported that on August 3, 2026 it granted an aggregate of 50,000 restricted stock units (RSUs) to its newly appointed Chief Legal Officer, Chris Cheng. According to Cardlytics, the award was approved as a material inducement to Cheng’s employment under Nasdaq Listing Rule 5635(c)(4) and issued pursuant to the company’s 2022 Inducement Plan.

The RSUs will vest over 24 months: 25,000 shares are scheduled to vest on September 1, 2027, with the remaining 25,000 shares vesting quarterly over the following 12 months, in each case subject to Cheng’s continued service with Cardlytics through the applicable vesting dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) reported that on July 29, 2026, its Board’s Compensation Committee granted an aggregate of 10,320 restricted stock units (RSUs) to 10 newly hired employees. The awards were issued as material inducements to employment under Nasdaq Listing Rule 5635(c)(4) and made pursuant to the 2022 Inducement Plan.

According to Cardlytics, for each recipient, 50% of the RSUs vest on the first anniversary of the grant date, with the remaining 50% vesting quarterly over the following 12 months, subject to continuous service and the terms of the 2022 Inducement Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) announced the appointment of Chris Cheng as Chief Legal Officer, effective August 3, 2026. He will join the Leadership Team and lead the Legal and Compliance organization. Cheng succeeds former Chief Legal Officer Nick Lynton, who departed in July 2026.

According to Cardlytics, Cheng brings over 20 years of legal leadership at high‑growth technology and public companies, including senior roles at Zoom, Uber, Upwork, eBay, and most recently as Chief Legal Officer and Corporate Secretary at Iterable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) will release its financial results for the quarter ended June 30, 2026 on August 5, 2026, after market close. Management will host a conference call and live audio webcast at 5:00 p.m. Eastern / 2:00 p.m. Pacific, accessible via the Cardlytics investor relations website, with a replay available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
earnings date
-
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) reported Q1 2026 results: Revenue $34.3M, Billings $58.1M, and Adjusted Contribution $19.7M. The company completed the Bridg divestiture on March 24, 2026 and liquidated PAR shares to strengthen the balance sheet. Adjusted EBITDA turned positive to $0.2M and net loss narrowed to $4.5M. Q2 2026 guidance: Billings $61.0–$67.0M; Revenue $35.0–$40.0M; Adjusted Contribution $20.0–$23.0M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.15%
Tags
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) announced that on April 29, 2026 the Compensation Committee granted an aggregate of 272,000 restricted stock units to six newly hired employees as inducements under the 2022 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4). 50% vests at one year; remaining 50% vests quarterly over the next 12 months, subject to continuous service and plan terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) will release financial results for the first quarter ended March 31, 2026 on May 7, 2026 after market close. A conference call is scheduled for May 7 at 5:00 PM ET. A live audio webcast and subsequent replay will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
Rhea-AI Summary

Cardlytics (NASDAQ: CDLX) completed the sale of its Bridg assets to PAR Technology (NYSE: PAR) on March 24, 2026, receiving 1,810,222 shares of PAR common stock as consideration.

Cardlytics said it will strategically monetize the PAR position to pay down a majority of its line of credit, strengthen the balance sheet, and refocus on scaling its core Cardlytics platform; Bridg employees and operations transferred to PAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.89%
Tags
none

FAQ

What is the current stock price of Cardlytics (CDLX)?

The current stock price of Cardlytics (CDLX) is $4.15 as of September 12, 2026.

What is the market cap of Cardlytics (CDLX)?

The market cap of Cardlytics (CDLX) is approximately 24.4M.